Protalix BioTherapeutics, Inc. (PLX) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Protalix BioTherapeutics, Inc.

NYSE American•Healthcare•Biotechnology

$2.65-0.02(-0.01%)Pre-market

Market Cap

$215.96M

P/E

11.4x

P/S

2.7x

P/B

3.0x

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.

How this company scores

GoodMetricSide Score: 71/100

Strongest: Profitability (22/25); weakest: Cash & Earnings Quality (13/25).

Profitability22/25

Growth21/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality13/25

Strengths

Growing revenueStrong marginsHigh ROERising earnings

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 11.4x5y range 10.9x – 50.2x

Currently below its 10-quarter median.

P/S · 2.7x5y range 1.0x – 3.3x

Currently above its 20-quarter median.

P/B · 3.0x5y range 2.3x – 293.0x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 4 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $215.96M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $80.62M
Q. Revenue: $19.90M
TTM EBITDA: $25.59M
TTM Op. Income: $23.29M
Q. Op. Income: $4.67M
TTM Net Income: $18.95M
Q. Net Income: $3.78M
EPS: $0.05
Shares Out.: $79.99M

$80.62M in TTM revenue grew 30.1% YoY, reaching $19.90M last quarter. TTM EBITDA of $25.59M and TTM operating income of $23.29M show growth is flowing through to the bottom line. TTM net income of $18.95M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 2 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: 25.5%
Op. Margin: 23.5%
Net Margin: 19.0%

Op. margin of 23.5% is up 16.0% YoY — cost efficiency is improving. Net margin at 19.0% Over the past year, operating margin is up 214% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 11.4x
P/S Ratio: 2.7x
P/B Ratio: 3.0x

At 11.4x P/E, the stock trades below typical market levels. P/S of 2.7x and P/B of 3.0x provide additional context. P/E sits below typical market levels while revenue is growing. Over the past year, P/E is down 77% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $110.34M
Cash: $27.42M
Long-Term Debt: N/A
Book Value: $71.40M
D/E Ratio: N/A
Debt/EBITDA: 0.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-10.40M
TTM Free Cash Flow: $7.67M
FCF Margin: 9.5%
FCF / Net Income: 0.4

TTM FCF of $7.67M on $-10.40M in operating cash flow. The FCF / Net Income ratio of 0.4x means cash covers only part of net income — earnings quality needs attention. Over the past year, free cash flow is up 323% — a weakening trend.